73 related articles for article (PubMed ID: 38748746)
21. HepaticIschemia/Reperfusion Injuryinvolves functional tryptase/PAR-2 signaling in liver sinusoidal endothelial cell population.
Song J; He Z; Yang M; Yu T; Wang X; Liu B; Li J
Int Immunopharmacol; 2021 Nov; 100():108052. PubMed ID: 34454294
[TBL] [Abstract][Full Text] [Related]
22. Edoxaban, a direct oral factor Xa inhibitor, ameliorates coagulation, microvascular thrombus formation, and acute liver injury in a lipopolysaccharide-induced coagulopathy model in rats.
Morishima Y; Shibutani T; Noguchi K; Ito Y; Honda Y
J Thromb Thrombolysis; 2021 Jul; 52(1):9-17. PubMed ID: 33534029
[TBL] [Abstract][Full Text] [Related]
23. Use of direct-acting oral anticoagulants in solid organ transplantation: A systematic review.
Bixby AL; Lichvar AB; Salerno D; Park JM
Pharmacotherapy; 2021 Jan; 41(1):28-43. PubMed ID: 33155327
[TBL] [Abstract][Full Text] [Related]
24. The Impact of Dabigatran Treatment on Sinusoidal Protection Against Hepatic Ischemia/Reperfusion Injury in Mice.
Noguchi D; Kuriyama N; Hibi T; Maeda K; Shinkai T; Gyoten K; Hayasaki A; Fujii T; Iizawa Y; Tanemura A; Murata Y; Kishiwada M; Sakurai H; Mizuno S
Liver Transpl; 2021 Feb; 27(3):363-384. PubMed ID: 33108682
[TBL] [Abstract][Full Text] [Related]
25. Ischemia-reperfusion injury and its relationship with early allograft dysfunction in liver transplant patients.
Ito T; Naini BV; Markovic D; Aziz A; Younan S; Lu M; Hirao H; Kadono K; Kojima H; DiNorcia J; Agopian VG; Yersiz H; Farmer DG; Busuttil RW; Kupiec-Weglinski JW; Kaldas FM
Am J Transplant; 2021 Feb; 21(2):614-625. PubMed ID: 32713098
[TBL] [Abstract][Full Text] [Related]
26. Activated clotting factor X mediates mitochondrial alterations and inflammatory responses via protease-activated receptor signaling in alveolar epithelial cells.
Bukowska A; Schild L; Bornfleth P; Peter D; Wiese-Rischke C; Gardemann A; Isermann B; Walles T; Goette A
Eur J Pharmacol; 2020 Feb; 869():172875. PubMed ID: 31877279
[TBL] [Abstract][Full Text] [Related]
27. Correction to: protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases.
Heuberger DM; Schuepbach RA
Thromb J; 2019; 17():22. PubMed ID: 31708692
[TBL] [Abstract][Full Text] [Related]
28. Antiapoptotic Effect by PAR-1 Antagonist Protects Mouse Liver Against Ischemia-Reperfusion Injury.
Noguchi D; Kuriyama N; Ito T; Fujii T; Kato H; Mizuno S; Sakurai H; Isaji S
J Surg Res; 2020 Feb; 246():568-583. PubMed ID: 31653415
[TBL] [Abstract][Full Text] [Related]
29. Inflammasome-Mediated Inflammation in Liver Ischemia-Reperfusion Injury.
Jiménez-Castro MB; Cornide-Petronio ME; Gracia-Sancho J; Peralta C
Cells; 2019 Sep; 8(10):. PubMed ID: 31547621
[TBL] [Abstract][Full Text] [Related]
30. Proteinase‑activated receptor 2 deficiency is a protective factor against cardiomyocyte apoptosis during myocardial ischemia/reperfusion injury.
Wang M; Ma Y; Zhang T; Gao L; Zhang S; Chen Q
Mol Med Rep; 2019 Oct; 20(4):3764-3772. PubMed ID: 31485622
[TBL] [Abstract][Full Text] [Related]
31. Edoxaban Exerts Antioxidant Effects Through FXa Inhibition and Direct Radical-Scavenging Activity.
Narita Y; Hamamura K; Kashiyama M; Utsumi S; Kakizoe Y; Kondo Y; Ishitsuka Y; Jono H; Irie T; Mukoyama M; Saito H; Kadowaki D; Hirata S; Kitamura K
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450643
[TBL] [Abstract][Full Text] [Related]
32. Renoprotective effects of a factor Xa inhibitor: fusion of basic research and a database analysis.
Horinouchi Y; Ikeda Y; Fukushima K; Imanishi M; Hamano H; Izawa-Ishizawa Y; Zamami Y; Takechi K; Miyamoto L; Fujino H; Ishizawa K; Tsuchiya K; Tamaki T
Sci Rep; 2018 Jul; 8(1):10858. PubMed ID: 30022146
[TBL] [Abstract][Full Text] [Related]
33. Thrombin and factor Xa link the coagulation system with liver fibrosis.
Dhar A; Sadiq F; Anstee QM; Levene AP; Goldin RD; Thursz MR
BMC Gastroenterol; 2018 May; 18(1):60. PubMed ID: 29739329
[TBL] [Abstract][Full Text] [Related]
34. Sinusoidal protection by sphingosine-1-phosphate receptor 1 agonist in liver ischemia-reperfusion injury.
Ito T; Kuriyama N; Kato H; Matsuda A; Mizuno S; Usui M; Sakurai H; Isaji S
J Surg Res; 2018 Feb; 222():139-152. PubMed ID: 29273365
[TBL] [Abstract][Full Text] [Related]
35. The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells.
Vilaseca M; García-Calderó H; Lafoz E; García-Irigoyen O; Avila MA; Reverter JC; Bosch J; Hernández-Gea V; Gracia-Sancho J; García-Pagán JC
Hepatology; 2017 Jun; 65(6):2031-2044. PubMed ID: 28142199
[TBL] [Abstract][Full Text] [Related]
36. PAR2 regulates regeneration, transdifferentiation, and death.
Piran R; Lee SH; Kuss P; Hao E; Newlin R; Millán JL; Levine F
Cell Death Dis; 2016 Nov; 7(11):e2452. PubMed ID: 27809303
[TBL] [Abstract][Full Text] [Related]
37. Proteinase-activated receptor 2 (PAR2) in hepatic stellate cells - evidence for a role in hepatocellular carcinoma growth in vivo.
Mußbach F; Ungefroren H; Günther B; Katenkamp K; Henklein P; Westermann M; Settmacher U; Lenk L; Sebens S; Müller JP; Böhmer FD; Kaufmann R
Mol Cancer; 2016 Jul; 15(1):54. PubMed ID: 27473374
[TBL] [Abstract][Full Text] [Related]
38. Coagulation Factor Xa and Protease-Activated Receptor 2 as Novel Therapeutic Targets for Diabetic Nephropathy.
Oe Y; Hayashi S; Fushima T; Sato E; Kisu K; Sato H; Ito S; Takahashi N
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1525-33. PubMed ID: 27283743
[TBL] [Abstract][Full Text] [Related]
39. Comparative Study on the Cytoprotective Effects of Activated Protein C Treatment in Nonsteatotic and Steatotic Livers under Ischemia-Reperfusion Injury.
Matsuda A; Kuriyama N; Kato H; Tanemura A; Murata Y; Azumi Y; Kishiwada M; Mizuno S; Usui M; Sakurai H; Isaji S
Biomed Res Int; 2015; 2015():635041. PubMed ID: 26539519
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
